Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLu WangXMXiao‐Dong MoMHMingzhe Han

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates mesenchymal stem cells improved complete response rates in patients with acute graft-versus-host disease, indicating effective treatment potential.

Key Points

  • This trial aimed to evaluate the safety and efficacy of mesenchymal stem cells in patients with acute graft-versus-host disease.
  • Conducted as a multicenter, single-arm pivotal clinical trial.
  • Enrolled patients received mesenchymal stem cells and one second-line treatment for steroid-refractory involvement.
  • Infusions occurred twice weekly for four weeks, with assessments at days 28 and 56.
  • Overall response rate at day 28 was 63.0%.
  • Complete response rate at day 28 was 55.6%.
  • The incidence of adverse events was reported in fifty-three patients without infusion toxicity.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df06https://doi.org/10.1182/blood-2025-4237
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells as add-on therapy to anti-CD25 antibodies for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: a multicenter, single-arm, pivotal clinical trial2026 · 2 citations
  2. 2Umbilical cord-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a real-world study2026
  3. 3Gradual treatment effect from mesenchymal stem cell on steroid-refractory aGVHD in patients receiving above 8 infusions and with gut involvement: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial2024 · 1 citations
  4. 4Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial2024 · 27 citations
  5. 5Evaluating the safety of placenta mesenchymal stromal cells-derived exosomes (HP-MSCs-EV) in the treatment of steroid-resistant acute GVHD (SR-aGVHD) after allogeneic hematopoietic stem cell transplantation; phase I clinical trial2026